Researchers Develop Standards for Reporting Polygenic Risk Scores

Current reporting about the contribution of genetic variations to a person’s risk of disease is often incomplete and hard to interpret, according to the authors of a set of best practices for presenting such information.

Written byMarcus A. Banks
| 3 min read
polygenic risk score genetics genomics direct to consumer genome sequencing gwas

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: © ISTOCK.COM, DRAFTER123

Genomics researchers have unveiled a new set of reporting standards for the calculation of a person’s disease risk based on their genetic profile. Known as a polygenic risk score, this number attempts to quantify the contribution of multiple genetic variants to someone’s likelihood of developing conditions such as breast cancer or coronary heart disease. Generally speaking, a single mutation will have little effect on risk, but an agglomeration of mutations could boost the odds. The new standards aim to codify the way that researchers report their work about polygenic risk scores so that this work is comprehensible and usable by others.

“The framework that has been proposed here is coming from very reputable groups . . . who really have sat down and thought about how we define the terms of the field. This is what I find very exciting about it,” says Eimear Kenny, the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • marcus a. banks

    Marcus is a science and health journalist based in New York City. He graduated from the Science Health and Environmental Reporting Program at New York University in 2019, and earned a master’s in Library and Information Science from Dominican University in 2002. He’s written for Slate, Undark, Spectrum, and Cancer Today.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies